Page 135

Abril_2107

543 caso clínico Natalizumab en pacientes con enfermedad de Crohn - D. Fluxá et al Goldberg L. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn´s disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007; 13: 2-11. 13. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn´s disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83. 14. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, et al. Natalizumab for moderate to severe Crohn´s disease in Clinical practice: The Mayo Clinic Rochester Experience. Inflamm Bowel Dis 2012; 18: 2203-8. 15. Chen CH, Kularatna G, Stone CD, Gutiérrez AM, Dassopoulos T. Clinical experience of natalizumab in Crohn´s disease patients in a restricted distribution program. Ann Gastroenterol 2013; 26: 233-8. 16. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RS, Hanauer SB, et al. Natalizumab in Crohn´s disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013; 19: 621-6. 17. Juillerat P, Wasan S, Fowler SA, Friedman S, Pabby VK, Coukas JA, et al. Efficay and safety of Natalizumab ib Crohn´s disease patients treated a 6 Bosotn Academic Hospitals. Inflamm Bowel Dis 2013; 19: 2457.63. 18. Singh N, Deshpande R, Rabizadeh S, Dubinsky M. Real world experience with Natalizumab at a tertiary care pediatric IBD center. JGPN. 2016; 62: 863-6. 19. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy in Crohn´s disease. N Engl J Med 2005; 353: 362-8. 20. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-81. 21. Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of antibodies against JV virus in patients with refractory Crohn´s disease and effects of natalizumab therapy. Clin Gastroenterol Hepatol 2015; 13: 1919-25. 22. Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of Crohn´s disease patients after receiving natalizumab therapy. Gastroenterol Nurs 2009; 32: 327-59. 23. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn´s disease. Inflamm Bowel Dis 2013; 19: 2577-83. 24. Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, et al. Impact of JC virus antibody testing in patients with Crohn´s disease with loss of response to infliximab: A Markov Model. Inflamm Bowel Dis 2013; 19: 2625-33. 25. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalophaty. N Engl J Med 2012; 366: 1870-80. 26. Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41: 1227-36. 27. Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV. Efficacy and safety of natalizumab and vedolizumab for the management of Crohn´s disease: A systematic review and meta-analysis. Inflamm Bowel Dis 2015; 21: 1695-708. 28. Ge WS, Fan JG. Integrin antagonists are effective and safe for Crohn´s disease: A meta-analysis. World J Gastroenterol 2015; 21: 4744-9. 29. Camacho-Halili M, George R, Gottesman M, Davis-Lorton M. An approach to natalizumab hypersensitivity a case series of induction of tolerance. Mutl Scler 2011; 17: 250-3. Rev Med Chile 2017; 145: 538-543


Abril_2107
To see the actual publication please follow the link above